Mesothelioma Missouri Law

Actos Warning : Some scientists believe this may help improve your outcome from treatment. If you smoke a pipe or cigar, you may also have an increased risk for developing bladder cancer, but cigarettes are the main culprit behind bladder cancer today.

Chronic inflammation of your bladder may also place you at an increased risk of developing a specific type of bladder cancer called squamous cell carcinoma. Inflammation occurs when one has an untreated urinary tract infection, bladder stones, an indwelling bladder catheter, or an infection with a parasite called Schistosoma haematobium. Paraplegics or quadriplegics who require a catheter to drain their bladders and those who live in areas where S. haematobium is common are at greatest risk.

More information on Actos Warning

Saridon (phenacetin) and Cytoxan (cyclophosphamide) are two other substances that can increase your risk of bladder cancer. Phenacetin is a pain medicine that is no longer used that was previously shown to be associated with bladder cancer. Cytoxan is a drug used for chemotherapy that has been associated with bladder cancer. This may sound puzzling as you wonder, “how does one drug used to treat cancer cause another cancer?” Cytoxan itself is not the problem. Most medications are broken down by our bodies into components before being eliminated in our stool or urine. One of the byproducts of cyclophosphamide, called acrolein, can irritate the wall of your bladder, causing a lot of blood in your urine. Over time, this can increase the risk of developing bladder cancer.

Information from other sources on Actos Warning

A history of radiation therapy for a pelvic cancer may increase your risk of bladder cancer. Radiation has a role in the treatment of prostate, cervical, and ovarian cancers. Although the radiation is focused on the involved organ, the bladder and other surrounding structures also absorb radiation that sometimes damages the urothelium and leads to cancer.

Our use of the term or terms Actos Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Warning visit our site often.

http://www.seedol.com

Actos Warning : Much attention has been paid to the influence of diet on cancer risk and treatment. Thus far, some scientists have suggested that vegetables, fresh fruits, and some fermented milk products appear to decrease one’s risk of developing bladder cancer. A few foods thought to increase the risk of developing bladder cancer are foods rich in animal fat, diose containing a lot of cholesterol, fried foods, and processed meat with various additives. We are not sure of the exact influence of diet on bladder cancer at this point in time. Scientists around the world are working on uncovering potential links between diet and bladder cancer.

ARE THERE VARIOUS TYPES OF BLADDER CANCER?

As with other cancers that affect different body parts, there are multiple types of bladder cancer. To better understand them, let’s separate bladder cancer into two different groups: primary tumors that originate in the bladder and secondary tumors that spread to the bladder from other places.

More information on Actos Warning

Primary bladder cancers form within the bladder. Over 90 percent of primary bladder cancers in the United States are of the urothelial or transitional subtype. These form along the inner lining of the bladder. The second most common type of primary bladder cancer in the United States is squamous cell carcinoma, making up approximately 5 percent of all cancers diagnosed. These are often diagnosed in individuals whose bladder has been chronically irritated by an infection, stones, or an indwelling catheter. The third most common subtype of bladder cancer in the United States is adenocarcinoma, accounting for approximately 2 percent of all diagnosed cases. These typically form near the dome of the bladder. There are other types of primary bladder cancer, but these are very rare. If necessary, your urologist will speak to you about these rare types.

Information from other sources on Actos Warning

Secondary cancers form somewhere else in the body and spread to the bladder. Other tumors can get to the bladder by using the bloodstream, your lymphatic system, or directly from an organ close to the bladder. Other cancers that spread to the bladder, in order of decreasing frequency, are melanoma, colon cancer, prostate cancer, lung cancer, and breast cancer.

Now that we’ve discussed some of the basics concerning bladder cancer, let’s examine how you should go about choosing a medical team to treat your cancer.

Our use of the term or terms Actos Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Warning visit our site often.

http://www.seedol.com

Actos Bladder Cancer : The patient will be encouraged to do deep breathing exercises to prevent lung collapse. This process is generally assisted with a small device called a spirometer. If the individual has a history of lung disease or is congested post-operatively, respiratory treatments with inhaled medication may be instituted and provided by a respiratory therapist.

Pain post-op is initially treated often via the epidural catheter. Intravenous medication may be given as an alternative and switched to oral pain meds once the individual is tolerating liquids. Many physicians order a PCA (patient controlled anesthesia) in which the patient pushes a button that releases pain medication via an intravenous line into the blood stream. Maximal amounts of drug administered are carefully controlled by settings on the PCA to allow safe, effective analgesia.

During the post-op period, you will meet regularly with an enterostomy nurse who will teach you the mechanics of caring for an ostomy and handling the ostomy appliance. Gradually, your pain will diminish, strength will increase, and diet will be advanced. Drains placed intraoperatively to siphon off any excess fluids from the abdomen will be removed when no longer needed. Depending on the individual’s age, general health, the surgery itself, and whether any complications have occurred, discharge to home can be expected after approximately seven to ten days.

More information on Actos Bladder Cancer

For most patients in reasonably good health, few if any complications are the rule. A host of complications can occur with any major surgical procedure and hospital stay. The major complications associated with Radical Cystectomy include

Bowel injury: During difficult dissection, small intestines may be inadvertently opened. These injuries are usually immediately recognized and repaired without difficulty. During removal of the bladder, the rectum may be entered. Assuming the patient has had a complete bowel prep prior to surgery, the rectum is usually readily repaired.

Vascular injury: During removal of the pelvic lymph nodes, entry into a major vein or artery may result in significant blood loss. Smaller, inconsequential veins or branches into larger veins are usually ligated with a suture or cauterized shut. Larger veins and arteries require repair with a fine vascular suture and needle. Troublesome bleeding can also occur during removal of the bladder and from deep in the pelvis after the bladder and prostate are removed. Bleeding is stopped through suture ligation, vascular clips, or cautery.

Abscess: An abscess is a pocket of pus located deep within the body. It may form from a bowel or urine leak, and generally will require drainage since antibiotics alone may not resolve it. If percutaneous drainage (drainage through the skin) is possible, the radiologist will drain the abscess. If this is not possible, the urologist will need to open the incision or make a new incision to allow the pus to be drained. A sizable abscess will generally not be cured without proper drainage. Left untreated, an abscess can result in sepsis, a life threatening bacterial infection.

Information from other sources on Actos Bladder Cancer

Bowel leak: When the bowel is reconnected after removing the section for the urinary diversion, healing may not be adequate and bowel contents may leak into the abdomen. A bowel leak often will present as a failure of the bowel to return to normal function, resulting in a distended abdomen with poor bowel sounds. Distention, ileus (poor bowel function) may occur after the bowels are working well and feeding has been going on for some time. Evaluation is usually accomplished with CT Scan and oral contrast. Immediate surgical correction may be necessary. Left untreated, a bowel leak will generally lead to an abscess or possibly a fistula (a drainage tract from the bowel which may extend out through the incision or drain). The incidence of bowel leak is increased if bowel has been exposed to prior radiation, most often from radiation used to treat prostate cancer in men and uterine cancer in women.

Bowel obstruction: When a piece of bowel is separated from the intestine to create the new urinary drainage system, the remaining bowel must be reanastomosed (brought back together). This may be accomplished via sewing the bowel together or through the use of staples. Sometimes the opening of the bowel connection may be obstructed secondary to swelling. If an obstruction does not clear after a reasonable time, reoperation may be required.

Erectile dysfunction: During a standard radical cystectomy in the male, the fine nerves which run along the base of the prostate to the penis are severed, resulting in loss of erections (impotence). If the individual having surgery still has good erections and is sexually active, these nerves can be attempted to be saved by modifying the surgery. Saving the nerves is more difficult to do, it takes more time, and is not always successful.

Female sexual dysfunction: In the female patient at the minimum, the section of the vagina contiguous to the bladder is removed. In the presence of extensive bladder cancer, more of the vagina may need to be removed. Narrowing and shortening of the vagina may result, making sexual intercourse difficult, painful, or impossible. The vagina is reconstructed intraoperatively so that sexual relations can continue. For those requiring major removal of the vagina, future reconstruction of the vagina by additional surgery can be accomplished once the individual has fully recovered and is free of cancer.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Actos Lawsuit :  When facing the prospects of chemotherapy, it is essential to have an oncologist who can inform you fully of the potential probable effectiveness of the chemotherapy being offered. Just as importantly, the toxicities of the chemotherapy must be fully reviewed. Of course, there are no absolutes when reviewing the potential for success and failure. Each individual’s cancer is unique. Some respond better than others to chemotherapy. General statistics regarding disease regression and remission are available. Absolute numbers for the individual are not.

After several courses of chemotherapy, an assessment of your clinical progress will be made. This will generally require a study such as a CAT scan, to check the response of the cancer to the chemotherapy. If progress is being made and the individual is tolerating the chemotherapy, a decision is then made to continue the chemotherapy to completion. If on the other hand, the cancer is not responding or the individual is not tolerating the therapy, a decision can be made to stop further chemotherapy, alter the present regimen, or try a different course of chemotherapy.

As new drugs are introduced and new combinations of drugs are tested, statistics regarding effectiveness are constantly changing. Side effects too can vary, depending on the individual. However, most patients will experience the side effects to various degrees, and these need to be fully understood prior to proceeding.

In the end, it is the individual’s decision as to whether to begin or end chemotherapy. For many, trying chemo and seeing the effect on the cancer is a sound decision. If the cancer does not respond or if the patient finds the side effects unacceptable, chemotherapy can be stopped. It is extremely important for you to have an oncologist who will work with you closely. Your oncologist should understand your feelings regarding cancer treatment fully.

More information on Actos Lawsuit

Cancer is defined as a group of diseases characterized by uncontrolled growth and spread of abnormal cells. Cells are the small building blocks of our body and most other living organisms. If the spread of these abnormal cells is not controlled, it can result in organ dysfunction and death. There are several cancers, each affecting various portions of the body. Cancer can be caused by external factors like cigarette smoking, exposure to certain chemicals, radiation, or infectious organisms. Internal factors that can lead to cancer include inherited mutations, hormones, and conditions affecting your immune system. Mutations are permanent changes in your hereditary material, and hormones are products of certain cells in our body that influence the function of other cells.

Although scientists have been able to uncover the cause of some cancers, there is still a great deal to be learned. One may go through his or her entire life without exposure to any of the previously mentioned factors and develop cancer. Men have a higher risk of developing cancer, with a slightly less than i in 2 lifetime risk in the United States compared with 1 in 3 for women. Although cancer is more common than you may think, doctors have figured out new ways to diagnose and treat cancer. By no means is cancer a death sentence; it can be managed and a lot of people diagnosed go on to live healthy and productive lives for many years after treatment.

Information from other sources on Actos Lawsuit

Ludwig Rehn, a German surgeon during the 19th century, is credited with the first explanation of one of the root causes of bladder cancer. He established a link between exposure to chemicals used in the production of colored textiles and the development of bladder cancer in factory workers. Although his discovery was not initially accepted, bladder cancer was soon recognized as an occupational cancer in factory workers. This may help explain the higher incidence of bladder cancer in industrialized nations.

Exposure to a number of chemicals has been associated with the development of bladder cancer. These include aniline dyes and other members of the aromatic amine family. People who work in occupations where exposure to these chemicals is common include textile workers, dye workers, rubber workers, painters, and even hairdressers.

Smoking is the most common cause of bladder cancer today. It increases your risk of developing bladder cancer 2- to 4-fold compared with people who don’t smoke. The risk of bladder cancer increases with the frequency and duration of smoking. For example, someone who smokes one pack a day for 20 years has a higher risk of bladder cancer than someone who smokes a few cigarettes on weekends. When you stop smoking you can slowly decrease the risk of bladder cancer, over the course of 20-30 years. If you currently smoke, it would be best to stop smoking.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

http://www.seedol.com

Actos Bladder Cancer :  While still awake, you will be transferred onto the operating room table and secured on it. If an epidural has not already been placed, one may be inserted. You may have an additional intravenous line placed. Next, your anesthesiologist will have you breathe through a mask placed over your nose and mouth. You will be given a mixture of agents which will allow you to become relaxed. Further anesthetics will result in an unconscious state. At this time, an endotracheal tube will be passed down your windpipe to provide oxygen, which is delivered automatically by a respirator, controlled by the anesthesiologist. The anesthesiologist will continuously monitor your heart rate, blood pressure, electrocardiogram, and tissue oxygenation throughout your operation.

Fluid balance may also be measured via an intravenous line passed close to your heart. Urine output will be followed. Antibiotics will be infused intravenously. Usually, compression stockings will be secured around your legs. These stockings periodically squeeze the legs to prevent blood from becoming stagnant, lowering the risk of blood clots forming in your legs, which can occur when you lie completely motionless for extended periods of time. A nasogastric tube will be passed through your nostril down your esophagus into the stomach, draining the stomach secretions during and after the surgery. A grounding pad will be placed on your side to allow for the safe use of electric current which is used to sometimes cut tissue and often in the cauterization of small bleeding vessels to stop bleeding.

Your abdomen will be prepared for surgery by shaving any hair and prepping the skin with an antiseptic solution. Female patients will have the vagina prepped with antiseptics as well. The surgical field will then be draped with sterile towels and sheets to prevent contamination from surrounding non-sterilized areas. Your upper body may be kept warm with a warming blanket. Your surgical nurse, surgeon, and assistant will all have thoroughly cleaned their hands and arms (scrubbed) and will then don a sterile gown and gloves. Their hair will be covered with a surgical cap, and they will be wearing masks over their mouths to prevent any contamination of the sterilized surgical field.

The standard operation is called Radical Cystectomy. This operation is accomplished through an incision which extends down the middle of the abdomen beginning at the level of the umbilicus and extending down to the pubic bone. The peritoneum (the sac around your intestines) is opened. The surgeon will examine the abdomen to make sure there is no evidence of cancer spread. Removal of the lymph nodes from the pelvis around the bladder is accomplished. The bladder is removed in its entirety along with the prostate and seminal vesicles in the male. In the female, the uterus and vagina are adjacent to the bladder and may be involved with local spread of cancer beyond the bladder. Consequently, the uterus and part of the vagina are removed. Since most females having a cystectomy are well past menopause, the ovaries are also removed, thus avoiding the possibility of future diseases including ovarian cancer.

More information on Actos Bladder Cancer

Once the bladder and surrounding organs are removed, the urinary tract must be reconstructed. This is most often accomplished by sewing the ends of the ureters into a piece of ileum (a section of small intestine) which is brought out through the skin as an ostomy. This form of reconstruction is called an ileal loop diversion. Since this reconstruction involves the urinary tract, the ostomy is referred to as a urostomy. Prior to sewing the ureters into the ileum, a biopsy of the ends of both ureters is examined by a pathologist to make sure there is no carcinoma in situ present. If cancer is found at the end of the ureter, this section is removed and the next higher level is examined by the pathologist to assure the ureter is free of cancer at the implantation site. If a neobladder is being planned, the prostatic urethra is examined by the pathologist to assure no cancer is present prior to proceeding further.

Transitional cell cancer extending into the urethra of a female patient or the prostatic urethra of a male patient would generally require urethrectomy at the time of cystectomy. Urethrectomy requires more dissection, potential for bleeding and infection, and possibly increased post operative drainage. It should therefore be performed only when necessary. Cancer located close to the bladder neck may raise the odds of cancer developing in a urethra which is left behind. The status of the urethra can be followed post cystectomy with washings sent for cytology. If cancer subsequently develops, a urethrectomy can be accomplished as a separate operation long after cystectomy has been done.

Information from other sources on Actos Bladder Cancer

At the conclusion of surgery, generally while still in the operating room, the endotracheal tube is removed when the patient is awake enough to breathe on his own. The patient will then be brought to the recovery room where he will be carefully observed by trained nurses in conjunction with the anesthesiologist and urologist. The individual is kept in the recovery room until conscious, breathing on his own and stable. Recovery room stays may be short, on the order of 30 minutes, or may extend to several hours, depending on how the individual is doing. If doing well, the patient will then be transferred to a floor in the hospital. If the individual’s surgery was particularly complicated, extended, or if the individual is unstable (irregular heart beat, low blood pressure, inability to be taken off the respirator), or if the individual has significant medical problems or has experienced a complication from surgery, transfer to an ICU (intensive care unit) may be warranted. In the ICU, there exists a much higher ratio of nurses to patients than on a standard postoperative floor, allowing for constant surveillance and care for critical patients. Also, if a respirator is required postoperatively, initial treatment in an ICU is usually necessary.

After transfer to the floor from the recovery room, the patient is often kept on bed rest for the rest of the day. The nasogastric tube is left in and placed to gentle suction to remove excess stomach fluids. Initially, nothing is allowed by mouth other than ice chips or sips of water. Adequate fluids and some nutrition are given via an intravenous catheter. By the following day, patients are often out of bed and sometimes walking with assistance. Sequential stockings on the lower legs are removed while ambulating, and discontinued once the individual is able to move about well. Traditionally, nasogastric tubes have been left in until the bowel activity returns (generally 3-4 days). This is generally heralded by the passing of flatus (gas) or the presence of active bowel sounds, which will be checked by your urologist with a stethoscope. Recent studies have indicated nasogastric drainage for this length of time may not be necessary and may impede normal breathing, leading to other problems. Some urologists are therefore removing the tubes earlier. Feeding is gradually introduced however, once bowel activity has returned.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Actos Side Effects:Your procedure will likely be scheduled at the hospital surgicenter as an outpatient. Depending 011 the extent of surgery and your general health, you may be required to stay in the hospital afterwards. There will be numerous forms to fill out, including consents for surgery and anesthesia. You will be asked whether or not you have a living will or power of attorney. Both the expected surgery and anesthesia planned will be fully discussed with you, including potential risks and alternatives. Your urologist will perform a history and physical exam to make sure you are fit for surgery. If you have multiple potentially serious medical problems, you probably have already had a pre operative visit with your internist, cardiologist or appropriate primary care physician.

You will be asked whether or not you have any drug allergies, artificial joints, or other medical devices implanted, such as a pacemaker. An IV (intravenous line) will be inserted into a vein in your hand or arm. You will be wheeled on your stretcher to the cystoscopy room and then positioned on the cystoscopy table. Small paste on leads will be placed to monitor your heart and a small device will be clipped over your finger to monitor the level of oxygen in your blood. You will then be given your appropriate level of anesthesia. Depending on the size and location of the tumor(s) and the difficulty of the procedure, your urologist will likely make a recommendation to you regarding the level of anesthesia required. He may give more than one choice. Risks of each will be reviewed with you by the anesthesiologist or nurse anesthetist (a nurse specialized in giving anesthesia).

Local with sedation: a numbing gel is squirted into your urethra and you are given intravenous sedation. Advantages include the lowest level of anesthesia, potentially with the least side effects and risks and quickest post op recovery from anesthesia. Many individuals are concerned they will experience pain. For small tumors and relatively minor surgery, this is an excellent form of anesthesia with very few patients experiencing pain or adverse reactions. If you do experience significant discomfort, your level of anesthesia can be changed to spinal or general.

Spinal anesthesia: accomplished by passing a fine needle into the lower spinal canal and injecting an anesthetic. Advantages include the ability to provide almost complete blockage of all pain and sensation during the surgery. The patient can continue to breathe on his own (a possible advantage for those with lung disease). Disadvantages include the occasional difficulty in giving the spinal (usually done rapidly with minimal pain, but sometimes difficult with pain), slower recovery from anesthesia (the length of spinal anesthetic is based on the amount and type of agent used and can generally be timed to match fairly closely the anticipated length of your procedure) and the possibility of a post spinal headache (not very common, but can last a day or more and be moderate to severe).

More information on Actos Side Effects

General anesthesia: delivered through IV medications and anesthesia in a gaseous mixture via a mask or endotracheal tube (a tube inserted down your throat into your trachea, your main airway). The choice of mask or endotracheal tube is generally decided by the anesthetist. This decision is based on the length of the anticipated procedure, your general health, and how easy it is to “ventilate” or provide oxygen to you with a mask alone. The advantage of general anesthesia is total blockade of all pain and sensation (you are unconscious). For healthy individuals with large tumors or with expected difficult surgery, this method is often the best form of anesthesia. For those in whom spinal anesthesia is not possible and a large tumor is present, general anesthesia is the best option.

For many years, hospitals required indiscriminate preoperative testing, often including numerous lab studies, chest X ray and EKG. Today, the medical industry is more cost sensitive. Most centers will require only necessary tests based on your age, medical history, and medications. An EKG is often requested for those with heart disease and for individuals over the age of 50. Specific labs are required if you have a chronic illness or are taking medication which can change the bodies normal chemical balance. Reserving blood from the blood bank is rarely required unless you present with a low blood count from hematuria or from another illness.

Information from other sources on Actos Side Effects

The urologist will often start by introducing a rigid cystoscope to examine the urethra and bladder. During the exam, your bladder will be filled with sterile water which travels through the scope. This is necessary to expand the bladder lumen fully, allowing a complete examination. Patients often are concerned too much fluid will be instilled, resulting in possible injury to the bladder or worse, a rupture. Because the water is instilled with only minimal pressure, bladder injury should not be a concern. The urologist can shut off the irrigation readily when the bladder is full and can empty the bladder at any time. After the cystoscopy is completed, the urologist then removes the bladder tumor(s).

If the tumors are small, he may simply use a biopsy forceps through the cystoscope (an instrument which has a small cup like end to remove pieces of tissue). Deep biopsies at the base of the tumor (especially when one is dealing with solid tumors as opposed to papillary variety) may be obtained using the same biopsy forceps. The tumors and deep biopsies are sent to the pathologist for examination. Additional biopsies from any suspicious areas or possibly the prostatic urethra may be done. After the tumor removal and biopsies are completed, electric current is used to stop any bleeding. The urologist steps on a pedal to turn the electric current on when the cable is touching the bleeding blood vessel.

Our use of the term or terms Actos Side Effects is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Side Effects visit our site often.

http://www.seedol.com

Multaq FDA :  The optimal duration of treatment with the oral nucleoside analogues is not known. Most doctors will probably anticipate giving these for at least one year. If at the end of a year of treatment there is loss of blood HBeAg (and rarely also HBsAg), treatment is considered a success and the drug may be stopped. However, this is achieved in only a minority of patients. Many more patients will have suppression of viral replication as assessed by undetectable blood viral DNA while taking the drug. But when the drug is stopped in most of these patients, viral replication will begin again and blood DNA will again be detectable. It is not clear if treatment in such patients should be maintained for another year, for several years, or for life, or if a different nucleoside analogue should be tried. It is also not known if prolonged treatment with nucleoside analogues will slow the progression of fibrosis, prevent hepatocellular carcinoma, or prolong life. Many doctors feel that at least patients with significant inflammation and/or fibrosis on liver biopsy, and possibly those with higher blood viral DNA levels, should be treated for the long term. However, the safety and efficacy of treatment with lamivudine, entecavir, or adefovir for hepatitis B for more than one year has not been firmly established. An informed patient and a hepatolo- gist should together make a decision about long-term duration of treatment with nucleoside analogues, with an understanding that all of the answers regarding efficacy and safety are not yet in.

Some patients with chronic hepatitis B will have a flare in liver inflammation as indicated by an elevation in blood ALT activity during treatment. This flare may paradoxically be associated with loss of HBeAg, resulting from the immune system being stimulated to destroy the virus-infected liver cells. Therefore, if a sudden rise in ALT activity occurs during treatment in an individual with chronic hepatitis B, therapy may be cautiously continued unless evidence of worsening liver function or failure is detected. A flare in inflammatory activity could also represent development of resistance to the drug, in which case the blood viral DNA will usually increase. And a flare in inflammatory activity could always indicate another problem or perhaps even a rare adverse event to the drug. It is therefore critical that a physician experienced in the medical treatment of chronic hepatitis B assess the patient very carefully to determine if the drug should be continued or stopped.

Who is more likely to respond to treatment for chronic hepatitis B? A shorter duration of infection correlates to a better chance of response. Therefore, individuals from countries where hepatitis B virus infection is endemic and who were likely infected at birth or in early childhood are less likely to respond. People infected as adults and who have been infected for less than three years usually have the best response. Younger patients are more likely to respond than older patients. Patients without cirrhosis will respond more often than those with cirrhosis; however, patients with greater inflammation on biopsy may surprisingly respond better than those with minimal inflammation.

More information on Multaq FDA

Interferon alpha and peginterferon alpha are administered by subcutaneous (under the skin) or intramuscular (into the muscle) injections. Most patients self-administer injections with small syringes similar to those used by diabetics to inject insulin. Most people choose to inject the interferon into the thigh; however, other areas such as the abdomen can also be injected. Patients should obtain brief training from a doctor or nurse before beginning self-injections.

Interferon alpha treatment for chronic hepatitis B is for sixteen weeks, with injections every day or three days a week depending on the dose. Peginterferon alpha treatment generally is for forty-eight weeks with injections once a week. Because low blood counts are a side effect of interferon alpha, patients should have their blood drawn and complete blood counts and platelet counts checked as their doctor instructs them after treatment has begun. ALT activity, bilirubin concentration, and albumin concentration should also be checked periodically during therapy. Patients should probably be seen by their doctors, or a nurse, at least once a month during treatment and instructed to contact their doctor if they experience side effects.

The most common and potentially serious side effects of interferon alpha and peginterferon alpha are low neutrophil counts and low platelet counts. Neutrophils, also called granulocytes, are a particular type of white blood cell important in fighting bacterial infections. Platelets are blood cells involved in clotting that may also be low in individuals with cirrhosis. As mentioned, patients should have their blood counts monitored during treatment with interferon alpha. If the neutrophil or the platelet count falls below certain levels, the dose of interferon alpha may have to be temporally reduced or the drug may even have to be discontinued.

Information from other sources on Multaq FDA

There are many other side effects of interferon alpha and peginterferon alpha therapy beside low blood counts. The most common is development of flu-like symptoms. These can be quite disabling and include fever, cold sweats, shaking chills, muscle aches and pains, and joint aches and pains. Flu-like symptoms are usually worse near the start of treatment and less common later in the course of therapy. To help tolerate mild to moderate flu-like symptoms, I generally recommend that patients inject the interferon about an hour before going to sleep and take acetaminophen just before injecting the interferon. The acetaminophen will provide some relief from symptoms and, if taken at bedtime, possibly help the patient to sleep through the side effects. Flu-like symptoms rarely require stopping treatment, but on occasion they are so intolerable that there is no other option.

Interferon alpha and peginterferon alpha can aggravate diabetes mellitus and thyroid disorders. Patients with diabetes mellitus who are treated with interferon alpha should carefully monitor their blood sugars. Patients with thyroid disease—and possibly all treated patients— should have blood tests for thyroid function checked periodically during treatment. Significant abnormalities in blood sugar or thyroid tests may necessitate stopping treatment.

Our use of the term or terms Multaq FDA is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq FDA visit our site often.

http://www.seedol.com

Multaq Warning : What are the goals of therapy for chronic hepatitis B? The primary goal is to change the infection from replicative (blood HBeAg-positive or detectable DNA) to nonreplicative (blood HBeAg and DNA negative). Studies have shown that conversion from HBeAg-positive to HBeAg-negative after treatment for chronic hepatitis B is associated with a better patient outcome. Another goal is to decrease inflammation, as can be assessed by decreased blood alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities and, if performed, follow-up liver biopsy. A third goal is to slow progression of fibrosis, which can be assessed only by repeat liver biopsy. An elusive goal, achieved by very few patients, is loss of HBsAg from blood, which likely demonstrates a cure. Another goal is to decrease the chance of developing hepatocellular carcinoma, which may make reasonable the treatment of select patients with cirrhosis who can tolerate the drugs.

A major difficulty with these goals is that it is hard to determine if some of them are achieved. Loss of HBeAg, viral DNA, or HBsAg from blood is relatively easy to measure. Blood AST and ALT activities are also easy to measure as approximations of liver inflammation. However, assessment of fibrosis and accurate assessment of inflammation require repeat liver biopsies. Furthermore, progression of fibrosis, and the development of hepatocellular carcinoma, may only occur after years or even decades—longer than these drugs have been given to patients.

More information on Multaq Warning

Given that multiple drugs are not available and approved, this is a difficult question to easily answer. First, the patient should understand the treatment and the chances of obtaining the desired results. Second, the patient should understand the goals of treatment. Third, the adverse event profiles of the different drugs should be considered. Treatment with an alpha-interferon is associated with more side effects and is more difficult to tolerate than treatment with the oral nucleoside analogues.

As studies have shown that conversion from HBeAg-positive to HBeAg-negative after treatment for chronic hepatitis B is associated with a better outcome, this is the main goal of treatment in patients who are FiBeAg-positive. Ideally, loss of HBeAg should be associated with the emergence of antibodies against HBeAg, but this does nor always occur. For patients without cirrhosis, this is probably more often achieved after treatment with an alpha-interferon (15 to 40 percent) than with nucleoside analogues (10 to 20 percent). Therefore, in patients who have HBeAg in blood and can tolerate treatment with an alpha-interferon, I recommend trying it first. I may also try it in patients who are HBeAg-negative but have high blood concentrations of viral DNA. My preference would be to use a peginterferon, which gives better effective steady-state blood levels with less frequent injections. Although a peginterferon alpha is taken for a longer time period (forty- eight weeks compared co sixteen weeks), it is injected only once a week as opposed to every day or three times a week at fairly high doses. This likely makes taking peginterferon for a year much more tolerable than taking an unmodified interferon at high doses more frequently for a few months.

Information from other sources on Multaq Warning

For patients who cannot tolerate an alpha-interferon, or for patients who have tried one and either stopped because of adverse events or because they did not respond after a full course of treatment, I recommend trying a nucleoside analogue. While lamivudine is the oldest and the most inexpensive, about 20 percent of patients treated with lamivudine develop resistance in which a mutant virus arises and starts to replicate. Resistance is much less frequent with adefovir or entecavir. Emergence of resistance is detected by recurrence of replication during treatment after initial suppression. Viral replication during treatment is assessed by blood viral DNA concentrations. One possibility is to start a patient on lamivudine and periodically check blood hepatitis B virus DNA. If it remains detectable or becomes detectable after an initial decrease, the patient can be switched to adefovir or enrecavir. Another possibility, which more and more doctors are choosing, is to use adefovir or entecavir as the first-line nucleoside analogue. In some studies, entecavir has been shown to achieve better responses than lamivudine in terms of reducing blood viral DNA levels and possibly in improving inflammation on liver biopsy after forty- eight weeks of treatment.

An obvious question is: What about giving combinations of these drugs? That is an excellent question, but, unfortunately, there is not much data available yet about these drugs’ efficacy or toxicity when used together. A few studies have looked at peginterferon alpha combined with lamivudine and have shown that adding lamivudine to peginterferon alpha does not improve the chance of losing HBeAg from blood, suppressing blood viral DNA, or losing HBsAg from blood. Hence, this combination is not recommended. Other combinations will likely be studied over the next few years. Until more data are available, these combinations probably should not be used outside of approved clinical trials.

Unmodified interferon alpha is given at a fairly high daily dose every day or at a higher dose three days a week for sixteen weeks. Peginterferon alpha is given once a week for forty-eight weeks (some studies have given it for fifty-two weeks). At the end of treatment and several months afterward, patients are checkcd for blood HBeAg, antibodies against HBeAg, HBsAg, and viral DNA. As loss of HBeAg, ideally with the emergence of antibodies against it, and rarely loss of HBsAg can occur a few months after treatment is stopped, patients are checked again sometime after completing treatment. If several months after treatment the patient has lost blood HBeAg (or in rare cases HBsAg, too) and/or has undetectable blood DNA, treatment is considered a “success.” If blood HBeAg and viral DNA are detectable, treatment is considered to have “failed.”

Our use of the term or terms Multaq Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Warning visit our site often.

http://www.seedol.com

Actos Bladder Cancer :

Some tumors, including carcinoma in situ (CIS) tumors, are considered a high-grade bladder cancer because they characteristically have a high rate of progression to muscle- invasive tumors and also because they don’t have any differentiated features. The paradox is that they are only one cell thick, which usually correlates with lack of invasion. About 50 percent of the people diagnosed with CIS who have no other types of tumor present in the bladder will eventually have the CIS invade the muscle.

Recently, an extensive body of research work has suggested that abnormalities (known as “mutations”) of the genes that control the growth of bladder cancer may be important in helping to determine the prognosis of bladder cancer. While this is not yet routinely applied to clinical practice, preliminary studies have suggested that mutation of such genes as the P53 gene may be associated with more aggressive behavior of the tumor, with a greater tendency to spread. The P53 gene, which is part of the genetic makeup of the tumor, normally acts to suppress tumor growth; in some cancers, when an abnormality or mutation occurs, that tumor suppressive role is lost.

More information on Actos Bladder Cancer

Other genes may also be involved in this process, including those known as the Rb gene, Pi6 gene, and a gene that controls the epidermal growth factor receptor (EGFR). As this book is being written, a major clinical trial is studying whether these preliminary observations are true, and the final results are not known. We mention this to encourage you to discuss with your own physician the current state of the art of measuring genes and comparing the results with the outcomes of treatment of bladder cancer.

Information from other sources on Actos Bladder Cancer

Physicians and researchers can draw some general conclusions about bladder cancer and its diagnosis and treatment, but it is not always easy to predict how it will behave in a given individual.

Your physician and oncologist work with the pathologist to get an idea of your likely prognosis that is a5 accurate as possible, but the reality is that tumors of the same type don t always develop or progress in the same way. Nor do vthey always respond to treatment in the same way, and they don’t always follow a predictable pattern of recurrence.

Generally, one can say that the more deeply into the bladder layers cancer has spread, the more likely it is to recur. But some superficial cancers become invasive. And some don’t. Doctors and researchers don’t yet have all the key indicators to predict which superficial cancers will become invasive and recur and which ones wont.

In general, if you have been diagnosed with superficial urothelial cancer, you can expect a 40 percent chance that the cancer won’t recur, especially if you have a low-grade tumor where the cancer cells closely resemble normal bladder cells.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Multaq Liver Failure :Hepatocellular carcinomas are usually discovered as masses on CAT scans or ultrasound scans. The majority of patients with hepatocellular carcinomas have cirrhosis. In patients who have cirrhosis, a sudden deterioration in clinical condition may provide a clue to the presence of a hepatocellular carcinoma. Sometimes they will cause pain. Rising blood alkaline phosphatase activity may also suggest the diagnosis. Alpha-fetoprotein is a useful marker for diagnosis of hepatocellular carcinoma. It is often measured as part of routine screening in patients with chronic hepatitis B and chronic hepatitis C. Rising blood alpha-fetoprotein concentration in someone with chronic liver disease suggests the development of hepatocellular carcinoma. CAT or ultrasound scans should be performed in such instances. About 70 percent of patients with hepatocellular carcinoma have elevated blood alpha-fetoprotein concentrations. It is not specific for hepatocellular carcinoma, as individuals with other types of cancer—especially testicular—may also have elevated blood concentrations.

Ihe definitive diagnosis of hepatocellular carcinoma is made by biopsy. Usually, the liver mass is biopsied by a radiologist under CAT scan or ultrasound guidance. Sometimes, it is biopsied using a laparoscope, a fiber-optic instrument that is inserted into the abdomen. Occasionally, open surgical biopsy is necessary.

Hepatocellular carcinoma is curable by surgery only if the tumor is small. Surgery may not be possible in individuals with advanced cirrhosis. If surgery is contemplated, extensive presurgical evaluation by CAT scanning, magnetic resonance scanning, and angiography (injection of dye into the hepatic artery foilowed by X-ray) is required. Some patients with cirrhosis and small hepatocellular carcinomas confined to the liver may be treated by liver transplantation. For large tumors, or cancer that has spread beyond the liver, chemotherapy, ligating (tying) or embolization (clotting) of the hepatic artery, alcohol injection into the tumor, or radiation may relieve symptoms and prolong life, though none is curative. Patients may also opt for enrollment in clinical trials utilizing these and other experimental procedures.

The prognosis after treatment of hepatocellular carcinoma depends upon the size of the tumor and the extent to which the liver has been already damaged by cirrhosis. For patients with hepatocellular carcinomas that are deemed to be surgically resectable, the five-year survival rate after surgery is 10 to 30 percent. Rare hepatocellular carcinomas, often discovered in young women without cirrhosis, are a fibrolamellar variant that has a better prognosis after surgical resection. Patients with advanced cirrhosis generally do poorly after surgical resection and should be considered for possible liver transplantation if the tumors are small and have not spread. At the present time, not much data are available regarding survival rates after liver transplantation for small tumors. For patients with hepatocellular carcinomas confined to the liver in whom complete surgical removal of the tumor is not possible, the five-year survival rate is about 1 percent. Virtually no patients with hepatocellular carcinoma that has spread beyond the liver survive for long- most die within a few months.

More information on Multaq Liver Failure

Cholangiocarcinomas can arise in both the liver and the bile ducts outside the liver. Cholangiocarcinomas are usually discovered first on radiological studies and diagnosed by biopsy. Carcinoembryonal antigen, or CEA, may be elevated in the blood of patients with this tumor. In some parts of the world, liver fluke (Opisthorcbis sinensis or Clonorchis sinensis) infection is a predisposing risk for development of cholangiocarcinoma. Patients with primary sclerosing cholangitis are also at increased risk for development of cholangiocarcinomas.

The prognosis of cholangiocarcinoma is similar to that for hepatocellular carcinoma. Small tumors may be surgically resected in rare cases only; otherwise, the patient may undergo liver transplantation. Patients with cholangiocarcinomas that cannot be surgically resected, or have spread beyond the liver, have a poor prognosis.

Patients with hemangiomas are usually asymptomatic, and the condition is almost always diagnosed incidentally when ultrasound, CAT scan, or other imaging studies are undertaken for other reasons. In some instances, a patient with a hemangioma will come to the doctor with abdominal pain, nausea, vomiting, or a mass that can be felt in the upper abdomen. Very rarely, patients will come with anemia or low platelet counts resulting from red blood cells or platelets that are trapped and/or destroyed within the tumor. In extremely rare instances, a hemangioma can rupture, usually after abdominal trauma.

A diagnosis of hemangioma is made using special imaging studies. Routine ultrasound may be suggestive but is not always diagnostic. Definitive diagnosis can usually be made by a tagged red blood cell scan, MRI scan, or dynamic CAT scan performed after intravenous contrast dye is given.

Information from other sources on Multaq Liver Failure

Focal nodular hyperplasia is characterized by benign nodules in the liver. Like hepatic adenomas, focal nodular hyperplasia occurs primarily in women. Birth control pills may predispose women to this condition. Most patients with focal nodular hyperplasia do not have symptoms, but a mass can sometimes be felt in the abdomen. Small lesions may have to be resected because of the chance of rupture.

Nodular regenerative hyperplasia is a condition characterized by nodules without scar tissue throughout the liver. Patients with nodular regenerative hyperplasia can sometimes develop portal hypertension and associated complications such as esophageal varices and ascites. Sometimes, liver transplantation may even be required to treat the complications of portal hypertension.

Partial nodular transformation is characterized by nodules surrounded by scar tissue in the liver. Patients with partial nodular transformation usually have portal hypertension.

Our use of the term or terms Multaq Liver Failure is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Liver Failure visit our site often.

http://www.seedol.com